Ptc Therapeutics (PTCT) Cash from Operations (2012 - 2026)

Ptc Therapeutics' Cash from Operations history runs 15 years deep, the most recent figure standing at 59042000.0 for Q1 2026.

• On a quarterly basis, Cash from Operations fell 106.79% year-over-year to 59042000.0 in Q1 2026; TTM through Mar 2026 was 217949000.0, a 131.51% decrease from a year earlier, with the FY2025 full-year figure at 711196000.0, up 760.42% from the prior year.
• Cash from Operations retreated to 59042000.0 in Q1 2026 per PTCT's latest filing, from 34273000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 870103000.0 in Q1 2025 and bottomed at 165963000.0 in Q4 2022.
• The 5-year median for Cash from Operations is 55242000.0 (2022), against an average of 1729058.82.
• Across the five-year window, Cash from Operations tumbled 430.28% in 2024 and surged 1129.64% in 2025, its largest moves.
• Year by year, Cash from Operations stood at 165963000.0 in 2022, then soared by 39.57% to 100288000.0 in 2023, then surged by 70.08% to 30004000.0 in 2024, then slipped by 14.23% to 34273000.0 in 2025, then sank by 72.27% to 59042000.0 in 2026.
• Per Business Quant, the three latest PTCT Cash from Operations figures stand at 59042000.0 (Q1 2026), 34273000.0 (Q4 2025), and 66301000.0 (Q3 2025).